Form 4: Glaukos Director Gilbert Kliman Reports Acquisition of Company Stock and Options

Glaukos Corporation Director Gilbert H. Kliman has reported the acquisition of additional common stock and stock options through restricted stock unit grants and option awards as part of the company's director compensation policy.

Summary

• Gilbert H. Kliman, a Director at Glaukos Corp (GKOS), reported transactions involving the acquisition of common stock and stock options.
• On January 2, 2025, Mr. Kliman acquired 461 shares of common stock at a price of $0, representing a grant of restricted stock units (RSUs) in lieu of annual director retainer fees. These units will vest in full on the one-year anniversary of the grant date.
• Following this transaction, Mr. Kliman beneficially owned 32,797 shares of common stock, which includes 3,072 unvested RSUs and deferred vested RSUs.
• On May 29, 2025, Mr. Kliman acquired an additional 2,108 shares of common stock at a price of $0, also through a grant of restricted stock units under the Issuer's Director Compensation Policy. These units also vest in full on the one-year anniversary of the grant date.
• After the May 29, 2025 transaction, Mr. Kliman's beneficial ownership of common stock increased to 34,905 shares, including 4,285 unvested RSUs and deferred vested RSUs.
• Concurrently on May 29, 2025, Mr. Kliman was granted 3,149 stock options with an exercise price of $94.87. These options were granted pursuant to the Issuer's Director Compensation Policy, vest in full on May 29, 2026, and expire on May 29, 2035.
• The reported transactions are part of the company's standard director compensation policy.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative disclosures or unusual transactions.

Positives

• Director Gilbert H. Kliman received additional equity compensation, aligning his interests with shareholders.
• The grants of restricted stock units and stock options are part of the company's established Director Compensation Policy, indicating routine and structured compensation practices.
• The acquisition of shares at a $0 price reflects compensation in the form of equity, which is a common practice for director remuneration.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's future performance, only future vesting dates for the granted equity.

Industry Context

This Form 4 filing reports routine equity compensation for a director at Glaukos Corp, a medical technology company specializing in ophthalmic devices. Such compensation practices, involving restricted stock units and stock options, are common across the medical device and broader technology industries to align executive and director incentives with shareholder value.

Comparison to Industry Standards

• The compensation structure, involving grants of restricted stock units and stock options with vesting periods, is a standard practice for director compensation in publicly traded companies, particularly within the medical technology sector.
• Specific comparable companies or projects are not detailed in this filing, but the general approach aligns with typical corporate governance and compensation benchmarks for non-employee directors.

Corporate Governance

Related Party Transactions

• The reported transactions are related party dealings, as they involve equity compensation from Glaukos Corp to its Director, Gilbert H. Kliman. These are standard compensation arrangements.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by increasing his equity stake in the company. The dilution from these grants is typically minimal and expected as part of compensation plans.

Next Steps

• The restricted stock units granted on January 2, 2025, are expected to vest on January 2, 2026.
• The restricted stock units and stock options granted on May 29, 2025, are expected to vest on May 29, 2026.

Key Dates

Recommendation

Keywords

Glaukos Corp, GKOS, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Gilbert H. Kliman